Investment Rating - The investment rating for the company is "Buy" [1] Core Insights - The company reported revenue of 2.042 billion yuan and a net profit attributable to shareholders of 466 million yuan for 2024, reflecting year-on-year growth of 13.1% and 8.4% respectively, slightly exceeding previous expectations [2] - The company plans to distribute a final dividend of 0.388 HKD per share, with a payout ratio of 53.9% and a dividend yield of 12.7% [2] - The company has successfully acquired two new land parcels in Foshan, with a total construction area of 140,000 square meters [2] Summary by Sections Educational Business Performance - The educational segment showed steady growth, with total student enrollment increasing by 2.3% year-on-year to 58,000 and average tuition fees rising by 9.3% to 28,000 yuan per student [3] - Revenue from full-time higher education services, educational resource output, lifelong education services, and medical care business for 2024 were 1.626 billion, 221 million, 139 million, and 57 million yuan respectively, with year-on-year growth of 11.8%, 14.9%, -12.3%, and NA [3] Lifelong Education Business - The lifelong education segment experienced a decline, with revenue dropping by 12.3% to 139 million yuan due to a decrease in student enrollment [4] - The company implemented training projects for 94 institutions, covering nearly 41,000 students, and has registered approximately 2.3 million users on its online education platforms [4] Educational Resource Output - Revenue from educational resource output increased by 14.9% to 221 million yuan, supported by optimized cooperation structures and partnerships with 62 institutions [5] - The company launched several new platforms and training facilities, enhancing its integrated smart education platform [5] Medical and Health Business - The medical and health segment contributed 57 million yuan in revenue after being consolidated for 7 months, aligning with expectations [6] - The cardiovascular hospital received over 44,000 outpatient visits, and the occupancy rate of the nursing home exceeded 75% [6] Financial Performance and Forecast - The company’s adjusted net profit margin was 22.8% for 2024, with a gross margin of 47.4% [10] - Revenue forecasts for 2025 and 2026 are adjusted to 2.321 billion and 2.590 billion yuan respectively, with net profit estimates of 481 million and 610 million yuan [11] - The company maintains a PE ratio of 4/3/3X based on the current share price of 3.06 HKD, with a dividend yield of 12.7% [11]